In a tight funding environment, a significant portion of startups now secure pharma partnerships *before* their Series A. This pre-validation has become a major draw for VCs, signaling a shift where corporate buy-in is needed to de-risk early-stage science for investors.
Instead of relying on finding novel targets, a key strategy in neuropsychiatry is to revisit failed compounds that showed efficacy signals. Companies use modern chemistry and delivery to engineer solutions that separate efficacy from the historical liabilities that halted development, turning past failures into new opportunities.
Congress consistently rejects proposals to slash NIH funding due to deep bipartisan popularity. This support is strategically reinforced by the NIH's deliberate policy of distributing research grants across the country, ensuring almost every member of Congress has a constituent institution benefiting from the funds.
Flush with cash from their GLP-1 franchises, Eli Lilly and Novo Holdings have become the most active participants in Series A biotech funding. They are leveraging their deep pockets to stimulate company formation and strategically branch into new therapeutic areas, shaping the next wave of innovation.
Despite big pharma's focus on scalable RNA technologies, Series A funding shows a surprising resurgence in investment for cell and gene therapy. This suggests early-stage VCs see significant unsolved value in areas like targeted delivery and gene editing, bucking the broader clinical and commercial narrative.
The issue with mass-marketed compounded drugs like Wegovy extends beyond IP infringement. It attacks the fundamental "social contract" of biopharma: companies invest billions in R&D for a period of market exclusivity. Allowing compounded copies to bypass this system erodes the incentive for all future drug development.